An observational study evaluating preexposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate for the prevention of sexually acquired HIV infections

Trial Profile

An observational study evaluating preexposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate for the prevention of sexually acquired HIV infections

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Sep 2015

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Sep 2015 New trial record
    • 02 Sep 2015 According to a Kaiser Permanente media release, results from this trial were published in the journal, Clinical Infectious Diseases.
    • 02 Sep 2015 Results published in a Kaiser Permanente media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top